Hugues Dolgos, Nerviano Medical Sciences CEO
September 21, 2022 11:24 AM EDTUpdated September 26, 12:56 PM
Deals
R&D

Mer­ck KGaA teams up with Ital­ian on­col­o­gy group in PARP1 de­vel­op­ment deal

Paul Schloesser

Associate Editor

An Ital­ian group has al­lied it­self with Mer­ck KGaA in an on­col­o­gy li­cens­ing deal, seek­ing to get in on the mar­ket op­por­tu­ni­ty and ex­pand its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times